A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms

Yong Gao, Hao Gao, Guangfu Wang, Lingdi Yin, Wenbin Xu, Yunpeng Peng, Junli Wu, Kuirong Jiang, Yi Miao, Yong Gao, Hao Gao, Guangfu Wang, Lingdi Yin, Wenbin Xu, Yunpeng Peng, Junli Wu, Kuirong Jiang, Yi Miao

Abstract

Pancreatic neuroendocrine neoplasms (pNENs) are a group of clinically rare and heterogeneous diseases of the pancreas. However, the prognostic factors for this disease in patients still remain controversial. The purpose of our study is to evaluate the predictive roles of those prognostic factors for pNENs. All related articles published until Sep 17, 2017 were identified via PubMed, EMBASE, Web of Science, Ovid and the Cochrane Library. Studies that examined the prognostic factors of pNENs were enrolled. 17 articles (2822 patients) were finally included in this study. The pooled data suggested that patients with positive surgical resection margin and lymph node, advanced G stage and TMN stage, organ metastasis, vascular invasion and the necrosis of specimens had a decreased overall survival for pNENs. Similarly, patients with functional tumors might have a poor prognosis. However, age, gender, surgical type and size of tumor could not be regarded as prognostic factors for pNENs. Our analytic data demonstrated that surgical resection margin, G stage, TMN stage, lymph node, metastasis, vascular invasion and the necrosis could be prognostic factors for pNENs. Our study may assist doctors to screen patients with different prognosis more efficiently during follow-up and select appropriate treatment measures.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
The identification and selection process for this meta-analysis.
Figure 2
Figure 2
Forest plot of the association between pNENs and clinical feature and surgery prognostic factors. (A) The association between pNENs and gender. (B) The association between pNENs and age. (C) The association between pNENs and function. (D) The association between pNENs and surgical margin. (E) The association between pNENs and surgical type.
Figure 3
Figure 3
Forest plot of the association between pNENs and pathology related prognostic factor. (A) The association between pNENs and G stage. (B) The association between pNENs and lymph node invasion. (C) The association between pNENs and vascular invasion. (D) The association between pNENs and metastasis.

References

    1. Halperin DM, Kulke MH, Yao JC. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. Annual review of medicine. 2015;66:1–16. doi: 10.1146/annurev-med-061813-012908.
    1. Yang M, et al. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2014;43:1003–1008.
    1. de Herder WW, Rehfeld JF, Kidd M, Modlin IM. A short history of neuroendocrine tumours and their peptide hormones. Best Practice & Research Clinical Endocrinology & Metabolism. 2016;30:3–17. doi: 10.1016/j.beem.2015.10.004.
    1. Sun J. Pancreatic neuroendocrine tumors. Intractable & rare diseases research. 2017;6:21–28. doi: 10.5582/irdr.2017.01007.
    1. Ohmoto, A., Rokutan, H. & Yachida, S. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future. International journal of molecular sciences18, 10.3390/ijms18010143 (2017).
    1. Yao JC, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology. 2008;26:3063. doi: 10.1200/JCO.2007.15.4377.
    1. Cho JH, et al. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea. Pancreas. 2016;45:941–946. doi: 10.1097/MPA.0000000000000586.
    1. Dixon E, Pasieka JL. Functioning and nonfunctioning neuroendocrine tumors of the pancreas. Current opinion in oncology. 2007;19:30–35. doi: 10.1097/CCO.0b013e328011a236.
    1. Han JH, et al. [Clinical characteristics and malignant predictive factors of pancreatic neuroendocrine tumors] The Korean journal of gastroenterology=Taehan Sohwagi Hakhoe chi. 2009;53:98–105.
    1. Salaria SN, Shi C. Pancreatic Neuroendocrine Tumors. Surgical pathology clinics. 2016;9:595–617. doi: 10.1016/j.path.2016.05.006.
    1. Cheng Y, et al. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes. Frontiers of medicine. 2016;10:444–450. doi: 10.1007/s11684-016-0471-x.
    1. Tao M, et al. Analysis of risk factors affecting the prognosis of pancreatic neuroendocrine tumors. Chin Med J (Engl) 2014;127:2924–2928.
    1. Han X, et al. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas. 2014;43:526–531. doi: 10.1097/MPA.0000000000000065.
    1. Yang, M. et al. Epidemiology, diagnosis, surgical treatment and prognosis of the pancreatic neuroendocrine tumors: Report of 125 patients from one single center. Indian journal of cancer52, 343–349, 10.4103/0019-509x.176746 (2015).
    1. Demir R, et al. Necrosis and angioinvasion predict adverse outcome in pancreatic neuroendocrine tumors after curative surgical resection: results of a single-center series. World journal of surgery. 2011;35:2764–2772. doi: 10.1007/s00268-011-1262-9.
    1. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–1733. doi: 10.1093/annonc/mdn351.
    1. Arvold ND, et al. Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. International journal of radiation oncology, biology, physics. 2012;83:e337–343. doi: 10.1016/j.ijrobp.2011.12.068.
    1. Shiba S, et al. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. Pancreatology: official journal of the International Association of Pancreatology (IAP)… [et al.] 2016;16:99–105. doi: 10.1016/j.pan.2015.11.001.
    1. Wong J, et al. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. American journal of surgery. 2014;208:775–780. doi: 10.1016/j.amjsurg.2014.04.003.
    1. Zhou B, Duan J, Yan S, Zhou J, Zheng S. Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: A 12-year experience from a single center. Oncology letters. 2017;13:1157–1164. doi: 10.3892/ol.2017.5561.
    1. Taki K, et al. Significance of lymph node metastasis in pancreatic neuroendocrine tumor. Surgery today. 2017;47:1104–1110. doi: 10.1007/s00595-017-1485-y.
    1. Cienfuegos JA, et al. A single institution’s 21-year experience with surgically resected pancreatic neuroendocrine tumors: an analysis of survival and prognostic factor. s. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva. 2016;108:689–696.
    1. Bahra M, et al. Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas. Journal of gastroenterology and hepatology. 2007;22:930–935. doi: 10.1111/j.1440-1746.2007.04893.x.
    1. Yang M, et al. Surgical treatment and clinical outcome of nonfunctional pancreatic neuroendocrine tumors: a 14-year experience from one single center. Medicine. 2014;93:e94. doi: 10.1097/MD.0000000000000094.
    1. Gao C, Fu X, Pan Y, Li Q. Surgical treatment of pancreatic neuroendocrine tumors: report of 112 cases. Digestive surgery. 2010;27:197–204. doi: 10.1159/000253871.
    1. Ge W, Zhou D, Xu S, Wang W, Zheng S. Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic non-functioning pancreatic neuroendocrine tumors. International journal of surgery (London, England) 2017;39:127–134. doi: 10.1016/j.ijsu.2017.01.088.
    1. Boyar Cetinkaya R, Vatn M, Aabakken L, Bergestuen DS, Thiis-Evensen E. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors. Scand J Gastroenterol. 2014;49:734–741. doi: 10.3109/00365521.2014.903432.
    1. Ito T, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234–243. doi: 10.1007/s00535-009-0194-8.
    1. Cho MY, et al. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer research and treatment: official journal of Korean Cancer Association. 2012;44:157–165. doi: 10.4143/crt.2012.44.3.157.
    1. Baur AD, Pavel M, Prasad V, Denecke T. Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment. Acta radiologica (Stockholm, Sweden: 1987) 2016;57:260–270. doi: 10.1177/0284185115579932.
    1. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25:603–605. doi: 10.1007/s10654-010-9491-z.
    1. Das SL, et al. Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Gut. 2014;63:818–831. doi: 10.1136/gutjnl-2013-305062.
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit